基于mRECIST标组的ORR是OS独立预测因素 EASL临床实践指南推荐应用mRECIST标准的ORR预测OS 多项研究显示:基于mRECIST标准评估的缓解患者的OS显著高于无缓解者...

纳入标准是为了界定被认为最有可能从实验疗法中获益的人群，因此排除了不在临床研究方案进行治疗的可能性...

Thermal ablation is a safe therapeutic option to provide local control for 1 lung malignancies. Thermal ablation confers survival benefits in carefully selected patients: RF ablation with encouraging mid- and now long-term results. Studies...

RF Ablation Results: Comparative Therapies High-risk stage 1 and 2 NSCLC Modality 1-year 2-year 3-year 5-year LC DM Zemlyaketal SLR(25) 87.1% 12% 12% 3-ycancer-specific 90.6%,87.5%,90.2% 3-ycancer-free(p0.05) 60.8%,50%,45.6% RFA(12) 87.5%...

RF Ablation Results: Comparative Therapies M odality 5-yearsurvival StageINSCLC LocalRecurrence (mostwithin2years) Lobarresection 60-80% 能手术尽手术 6.4% Sub-lobarresection 60-70% 17.2% Image-guidedablation 27% 22.2%1 Externalbeamradiatio...

RF Ablation Results Pulmonary RFA: Long-term safety and efficacy in 153 patients1 - Local control group (n = 132) - 71 patients with stage I NSCLC - Overall survival rates: stage I NSCLC 78% 57% 36% 27% 27% 1-year 2-year 3-year 4-year 5-ye...

Post-ablation Care Through Discharge Post-procedural nurse and physician assessment Observation: 4 to 6 hours (outpatient) Limited or overnight admission for observation depending on clinical course and assessment Acceptable side effects -...

R adiofrequency A blation of P ulmonary TU mors R esponse E valuation ( RAPTURE) Trial Riccardo Lencioni, MD, Pisa, Italy Lencioni et al. Lancet Oncol 2008; 9:621-628. NSCLC (n = 33) CRC (n = 53) Other (n = 20) Total (n = 106) Gender (F :...

Locally recurrent cancerLimited or low volume metastases...

指南在一线系统治疗推荐首选索拉非尼（Child-Pugh A级[1类证据]或B7）和Lenvatinib（仅用于Child-Pugh A级），其他治疗推荐系统全省化疗（2B类证据），化疗方案在讨论中仅提及 FOLFOX4方案，并未明确表示推荐应用FOLFOX4方案，也没有推荐其他的化疗方案或化...